NIMG-26. EVALUATING THE DAYS GAINED RESPONSE METRIC IN CLINICAL TRIALS USING BEVACIZUMAB PLUS ADDITIONAL AGENTS FOR RECURRENT GLIOBLASTOMA

Determining effective therapies for patients with recurrent glioblastoma remains difficult especially in small early phase clinical trials. Currently utilized estimators of treatment response rely on two-dimensional measurements of tumor progression (e.g. RANO, RECIST, MacDonald) that have often fal...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Singleton, Kyle, Johnston, Sandra, Rickertsen, Cassandra, Keith Anderson, S, De Leon, Gustavo, Whitmire, Scott, Clark-Swanson, Kamala, Bendok, Bernard, Mrugala, Maciej, Porter, Alyx, Galanis, Evanthia, Swanson, Kristin
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2019
Konular:
Neuro-Imaging
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847498/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.697
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller